ImetelChat

Note this statement re Dr. Mascarenhas presentation:" This oral presentation reported significant dose-dependent reduction of mutation burden by imetelstat, including complete elimination of mutations in MF driver and non-driver genes. A greater than 20% reduction in variant allele frequency by imet...

Edward, yes we had all hoped to see Imetelstat used as front line therapy. The reasons for not doing so are murky at best and we have not seen adequate explanation for the absence of front line evaluation or combination therapy even though at least two strong preclinical studies suggest a promising ...

Was. Long ago.

The short answer is probably yes but not for a long time. The more pressing existential threat is Constellation Pharma and its BET inhibitor. It checks a lot of boxes: 1. spleen 2. symptoms 3. anemia 4. bone marrow. It has been tested alone and in combo with Rux. The results are impressive. I would ...

https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31769 Dr. Steensma is a world class premier clinical researcher. Note his recent move to Novartis from the Dana Farber. I have always been curious about his authorship on articles related to Imetelstat while his primary geographical r...

I suppose that should read "and we". bp

Every year there is a run up in stock price before ASH. Then a sell off. This year looks different. It's like the financial analysts haven't read the abstracts. Its like big Pharma haven't read the abstracts. Geron is presenting amazing data to support a drug that changes the natural history of dise...

Happy Thanksgiving to all. Well another virtual ASH coming up. So far no indication of KOL formal meeting post ASH and it is likely there will not be one. Nonetheless, it is a premier opportunity for some dramatic PR from Dr. Scarlett and Co and it is likely that strong statements regarding drug suc...

Thanks for posting, I think we have to accept that enrollment is not at the level Geron originally hoped and is due to a combination of factors, the major one probably being COVID but some contribution of the market availability and physician acceptance of Luspatercept is likely playing a role. Give...

CKTC, thanks for your observations and clarifications. It does seem a little peculiar that that Platzbecker presentation abstract has the data cut off we have noted of Feb 2000 without mention of an update. Clearly ASH provides the opportunity to up the TI data to a later data cut off date. Since th...

Recall that Dr. Scarlett said (in what seems like the distant past) that we would be informed when the 50% enrollment goal had been achieved in the MDS study. So far no notification. The shareholders letter addressed the COVID issue which is certainly playing a role but another less discussed reason...

This tender morsel will be irresistible to a large BP that has to see at this point the potential dominance in the area of myeloproliferative disorders. The solid evidence of direct effects on the malignant clone and variable alleles is becoming increasingly apparent. Geron seems to have differentia...

We have an upcoming meeting today. The financial analysts often seem to ask uninformed questions and miss the point and yes I know you read these posts. Often someone else is sitting in because the analyst is busy. So lets get to the positives and negatives. So far with two exceptions (disregarding ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607115/

Check out GRN-163 comments at the conclusion.

HI, thank you for posting this. I have been in medicine a long time. I can tell you that most of the advances I have seen are incremental. A true paradigm shift is a rare event. bp

HI, if Jeremy Smith owns a computer, he knows. He also probably reads this board. bp

HI, yes this apparent intellectual land grab by Dr. T probably caught Geron off guard and was not anticipated. I know you are an expert in IP so wouldn't you find this something unlikely to stand up in court? Was it legal slackness that allowed this to happen? Geron had a reputation for closely guar...